We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Judge: Pfizer’s Tamfadis Cost-Sharing Scheme Violates Anti-Kickback Laws
A federal judge has shot down Pfizer’s proposal to help heart failure patients afford Vyndaqel (tafamidis meglumine) and Vyndamax (tamfadis), oral formulations of an expensive cardiac medication for treatment of transthyretin amyloid cardiomyopathy.